Abstract
The incidence of prostate cancer (PCa) has increased worldwide in recent years along with the recommendation for prostate-specific antigen testing, and mortality has been declining owing to advances in fragmented and simplified access to treatment care. However, GLOBOCAN (Global Cancer Observatory) data show that this result is not true for all countries. It has been reported that the degree of PCa progression at diagnosis and survival rates differ among racial groups. Based on various comparisons between Caucasians and Asians, it was inferred that survival rates were higher in Asians despite the higher degree of progression at diagnosis, suggesting a better prognosis for life compared with Caucasians. The survey among Asian countries did not reveal any obvious differences among Asian subregions; rather, it inferred that the impact of the level of development among the countries was significant. The development of healthcare systems and medical care could improve PCa survival in developing countries.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.